Latest Healthcare News

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

EMVision Medical Devices has enhanced its AI-powered stroke diagnostic algorithm, achieving a notable 95% sensitivity and 80% specificity in recent tests. This progress sets the stage for upcoming pivotal trials and regulatory milestones.

LTR Pharma has appointed Associate Professor Darren Katz, a leading urologist and erectile dysfunction expert, to its Scientific Advisory Board, aiming to fast-track the development and commercialization of its innovative nasal spray treatments SPONTAN and ROXUS.

Chimeric Therapeutics has raised $6.6 million through a discounted two-tranche placement to accelerate its promising CAR-T and NK cell therapy clinical programs. The capital raise, strongly backed by institutional and professional investors, signals growing confidence in the company’s oncology pipeline.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Monash IVF Group has lowered its full-year profit guidance for FY2025 to $27.5 million, citing weaker market conditions and ongoing impacts from a recent operational incident in Brisbane. The company remains cautious as it monitors patient trends and legal costs.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

IMEXHS Limited reported robust FY24 growth and launched its AI-enabled medical imaging platform Aquila+, setting the stage for expected profitability and accelerated revenue in 2025.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.